Brucellosis vaccine is a vaccine for cattle, sheep and goats used against brucellosis. Currently, there is no vaccine available for humans.
The classification of Brucellosis Vaccines includes S19 Vaccine, RB51 Vaccine Strain and Other. And the proportion of S19 Vaccine in 2016 is about 86%, and the proportion is stable from 2012 to 2016.
Brucellosis Vaccines is widely used in Cattle, Sheep and Other Animal. The most proportion of Brucellosis Vaccines is for Cattle with market share about 60 in 2016.
China is the largest supplier of Brucellosis Vaccines, with a production market share nearly 31% in 2016. Europe is the second largest supplier of Brucellosis Vaccines, enjoying production market share nearly 17% in 2016.
China is the largest consumption place, with a consumption market share nearly 31% in 2016. Following China, South America is the second largest consumption place with the consumption market share of 17%.
The global Brucellosis Vaccines market is valued at 10 million US$ in 2018 and will reach 13 million US$ by the end of 2025, growing at a CAGR of 3.7% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Brucellosis Vaccines market based on company, product type, end user and key regions.
This report studies the global market size of Brucellosis Vaccines in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Brucellosis Vaccines in these regions.
This research report categorizes the global Brucellosis Vaccines market by top players/brands, region, type and end user. This report also studies the global Brucellosis Vaccines market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Ceva Sante Animale
Calier & Biologicos Laverlam
Market size by Product
RB51 Vaccine Strain
Market size by End User
Market size by Region
Central & South America
Rest of Central & South America
Middle East & Africa
The study objectives of this report are:
To study and analyze the global Brucellosis Vaccines market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Brucellosis Vaccines market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Brucellosis Vaccines companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Brucellosis Vaccines submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Brucellosis Vaccines are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (M Doses). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Brucellosis Vaccines market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.